Heron Therapeutics elects Kimberly J. Manhard as EVP of drug development.
M2 PHARMA-January 29, 2016-Heron Therapeutics elects Kimberly J. Manhard as EVP of drug development
(C)2016 M2 COMMUNICATIONS
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) revealed on Thursday the addition of Kimberly J. Manhard as executive vice president of its drug development.
Effective immediately, Manhard will report to the company's chief executive officer, Barry D. Quart, Pharm.D.
Since 2008, Manhard has served as senior vice president of Regulatory Affairs and Development Operations, corporate compliance officer and director at Ardea Biosciences, a wholly-owned subsidiary of AstraZeneca PLC.
Prreviously, Manhard has worked as president of her own consultancy firm, vice president of Regulatory Affairs for Exelixis as well as held multiple regulatory positions at Agouron Pharmaceuticals, a Pfizer Inc company, and Bristol Myers Squibb Company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 29, 2016|
|Previous Article:||Kentucky dental surgery recruits three new members to dental team.|
|Next Article:||The Pharmacy Technician Certification Board names new director of Strategic Alliances.|